跳至主要内容
临床试验/NCT02941341
NCT02941341已完成不适用

Ambispective Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Techniques in Spain.

Finox AG1 个研究点 分布在 1 个国家目标入组 1,222 人开始时间: 2016年10月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,222
试验地点
1
主要终点
Total number of oocytes retrieved

研究概览

简要总结

Non-comparative, observational, ambispective post-authorisation study (EPA-SP).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women aged ≥ 18 years
  • Currently undergoing an IVF or ICSI cycle or are oocyte-donors
  • Have completed controlled ovarian stimulation
  • Have received at least 5 doses of Bemfola®
  • Are pituitary suppressed with a GnRH antagonist
  • Have undergone oocyte retrieval
  • Have signed the Informed Consent Form

排除标准

  • Hypersensitivity to the active substance follitropin alfa, FSH or to any of the excipients listed
  • Presence of tumours of the hypothalamus or pituitary gland

结局指标

主要结局

Total number of oocytes retrieved

时间窗: 34-36 hours after hCG administration and after a maximum 16 days of r-hFSH treatment

次要结局

  • Quality of oocytes(At Day 4-5)
  • Number of fertilised oocytes(1 day after ovum pick-up)
  • Number and quality of transferred embryos(Day of embryo transfer, either 2,3 or 5 days after oocyte retrieval)
  • Fertilization and implantation rate(5 to 6 weeks after oocyte retrieval)
  • Incidence of serious adverse events, including moderate-to-severe OHSS(From Day 1 of stimulation)

研究者

发起方
Finox AG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验